Rituxan (rituximab) - Roche
Xolair (omalizumab) - Roche, Novartis
cyclophosphamide - Generic mfg.
methylprednisolone sodium succinate - Generic mfg.
Life-Threatening Eosinophilic Granulomatosis With Polyangiitis During Omalizumab Therapy for Chronic Urticaria: Missed Diagnosis, Induction, or Unmasking? (PubMed, Cureus) - Oct 3, 2026 - "The patient was initially treated with high-dose intravenous methylprednisolone, followed by rituximab...Treatment was escalated with therapeutic plasma exchange and intravenous cyclophosphamide...Whether omalizumab unmasked, coincided with, or induced EGPA remains uncertain. Clinicians should investigate unexplained, persistent eosinophilia as it could be an expression of a systemic disease." 
Journal • Asthma • Critical care • Dermatology • Dermatopathology • Eosinophilia • Eosinophilic Granulomatosis With Polyangiitis • Fatigue • Hematological Disorders • Immunology • Langerhans Cell Histiocytosis • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Urticaria • Vasculitis
http://www.ncbi.nlm.nih.gov/pubmed/42824523
 
Afroditi Boutou; Aikaterini Tzioutzia; Athanasios Zacharias; Athina Georgopoulou; Evdokia Sourla; George Margaritopoulos; Georgia Pitsiou; Panagiotis Zymaris
 
Oct 3, 2026
 
Prev Next